The effect of the current chemotherapy of MDR/XDR tuberculosis on QT interval changes in ECG
https://doi.org/10.21292/2075-1230-2019-97-11-19-22
Abstract
The objective of the study: to assess the effect of current chemotherapy on QT interval length in tuberculosis patients suffering from multiple/extensive drug resistance (M/XDR).
Subjects and methods. 87 patients (new cases and relapses) with destructive pulmonary MDR/XDR tuberculosis were followed up.
Results. During anti-tuberculosis therapy with regime V, the prolongation of QTc interval in the range of 450-500 ms was observed in 27.6% of MDR/XDR tuberculosis patients, which was most often recorded at the end of the 12th week of chemotherapy. The prolongation of QTc interval was reversible (in the majority of patients, QTc returned to its original values), it was not accompanied by clinical manifestations and ECG signs of ventricular arrhythmias, and did not require additional therapeutic measures (not in a single case). MDR/XDR tuberculosis patients receiving treatment with bedaquiline and fluoroquinolones need regular ECG examination to monitor changes in the QTc interval prolongation.
About the Authors
E. M. Zhukova
Novosibirsk Tuberculosis Research Institute
Russian Federation
Russian Federation
Elena M. Zhukova - Doctor of Medical Sciences, Leading Researcher
81a, Okhotskaya St., Novosibirsk, 630040 Phone/Fax: +7 (383) 203-83-57, +7 (383) 203-78-25, 203-83-65
L. G. Vokhminova
Novosibirsk Tuberculosis Research Institute
Russian Federation
Russian Federation
Lyudmila G. Vokhminova - Candidate of Medical Sciences, Head of Functional Diagnostics Department
81a, Okhotskaya St., Novosibirsk, 630040 Phone/Fax: +7 (383) 203-83-57, +7 (383) 203-78-25, 203-83-65
D. A. Kudlay
Immunology Research Institute by the Federal Medical Biological Agency
Russian Federation
Russian Federation
Dmitry A. Kudlay - Doctor of Medical Sciences, Leading Researcher of Laboratory
of Personalized Medicine and Molecular Immunology no. 71.
24, Kashirskoye Highway, Moscow, 115522 Phone: +7 (499) 617-79-22
References
1. Borisov S.E., Filippov А.V., Ivanova D.А., Ivanushkina T.N., Litvinova N.V., Garmash Yu.Yu. Efficacy and safety of chemotherapy regimens with bedaquiline in patients with respiratory tuberculosis: immediate and final results. Tuberculosis and Lung Diseases, 2019, vol. 97, no. 5, pp. 28-40. (In Russ.)
2. Mamaev А.N., Kudlay D.А. Vizualizatsiya dannykh v prezentatsiyakh, otchetakh i issledovaniyakh. [Data visualization in presentations, reports and trials]. Moscow, Prakticheskaya Meditsina Publ., 2011, 39 p.
3. Morozova T.I., Otpuschennikova O.N., Doktorova N.P., Danilov А.N. Experience of using bedaquiline in the treatment of pulmonary tuberculosis patients with multiple drug resistance. Tuberculosis and Lung Diseases, 2016, no. 2, pp. 29-35. (In Russ.)
4. Tikhonova L.Yu., Sokolova V.V., Tarasyuk I.А., Ekimenko А.M., Cherenkova M.А., Kudlay D.А. Experience of treatment of multiple drug resistant tuberculosis patients with bedaquiline in Amur Region. Tuberculosis and Lung Diseases, 2018, vol. 96, no. 6, pp. 45-50. (In Russ.)
5. Federalnye klinicheskiye rekomendatsii po diagnostike i lecheniyu tuberkuleza organov dykhaniya s mnozhestvennoy i shirokoy lekarstennoy ustoichivostyu vozbuditelya. [Federal clinical recommendations for diagnosis and treatment of respiratory tuberculosis with multiple and extensive drug resistance]. 3rd Edition, Moscow, 2015, 68 p.
6. Borisov S.E., Dheda K., Enwerem M. et al. Effectiveness and safety of bedaquilinecontaining regimens in the treatment of MDR- and XDR-TB: a multicentre study. Eur. Respir. J., 2017, vol. 49, pp. 6.
7. Kannankeril P., Roden D.M., Darbar D. Drug-Induced Long QT Syndrome. Pharmacol. Rev., 2010, vol. 62, no. 4, pp. 760-781.
8. Shovkun L., Kudlay D., Nikolenko N., Franchuk I. Accompanying therapy of patients with extensive drug-resistant (xdr) lung tuberculosis. Eur. Resp. J., 2018, vol. 52, pp. PA4747.
9. van Noord C., Eijgelsheim M., Stricker B.H. Ch. Drug- and non-drug-associated QT interval prolongation. Brit. J. Clin. Pharmacology, 2010, vol. 70, no. 1, pp. 16-23.
10. Zhang Y., Post W.S., Blasco-Colmenares E. et al. Electrocardiographic QT interval and mortality: a metaanalysis. Epidemiology, 2011, vol. 22, no. 5, pp. 660-670.
11. Zhang Y., Post W.S., Dalal D. et al QT-Interval Duration and Mortality Rate. Results from the Third National Health and Nutrition Examination Survey. Arch. Intern. Med., 2011, vol. 171, no. 19, pp. 1727-1733.
Review
For citations:
Zhukova E.M., Vokhminova L.G., Kudlay D.A. The effect of the current chemotherapy of MDR/XDR tuberculosis on QT interval changes in ECG. Tuberculosis and Lung Diseases. 2019;97(11):19-22. (In Russ.) https://doi.org/10.21292/2075-1230-2019-97-11-19-22
Views:
1313
Email this article 